{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:44:19Z","timestamp":1792842259681,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40268-022-00385-4","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T18:22:13Z","timestamp":1648232533000},"page":"131-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants"],"prefix":"10.1007","volume":"22","author":[{"given":"Fumihiko","family":"Koiwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Yazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5624-7553","authenticated-orcid":false,"given":"Daisuke","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"issue":"4","key":"385_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6(4):913\u201321. https:\/\/doi.org\/10.2215\/CJN.06040710.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"385_CR2","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1053\/j.ajkd.2011.08.009","volume":"58","author":"RN Moorthi","year":"2011","unstructured":"Moorthi RN, Moe SM. CKD\u2013mineral and bone disorder: core curriculum 2011. Am J Kidney Dis. 2011;58(6):1022\u201336. https:\/\/doi.org\/10.1053\/j.ajkd.2011.08.009.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"385_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10157-011-0502-5","volume":"15","author":"H Komaba","year":"2011","unstructured":"Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol. 2011;15(6):797\u2013809. https:\/\/doi.org\/10.1007\/s10157-011-0502-5.","journal-title":"Clin Exp Nephrol"},{"issue":"9684","key":"385_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","volume":"374","author":"WD Fraser","year":"2009","unstructured":"Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684):145\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(09)60507-9.","journal-title":"Lancet"},{"issue":"8","key":"385_CR5","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208\u201318. https:\/\/doi.org\/10.1097\/01.ASN.0000133041.27682.A2.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"385_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.nefro.2017.02.006","volume":"37","author":"M Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez M, Morales E, Gutierrez E, Polanco N, Hern\u00e1ndez E, M\u00e9rida E, et al. Calciphylaxis: beyond CKD\u2013MBD. Nefrologia. 2017;37(5):501\u20137. https:\/\/doi.org\/10.1016\/j.nefro.2017.02.006.","journal-title":"Nefrologia"},{"issue":"1","key":"385_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.03940510","volume":"6","author":"P Kandula","year":"2011","unstructured":"Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011;6(1):50\u201362. https:\/\/doi.org\/10.2215\/CJN.03940510.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"385_CR8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1046\/j.1523-1755.2001.0590031187.x","volume":"59","author":"WG Goodman","year":"2001","unstructured":"Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int. 2001;59(3):1187\u2013201. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.0590031187.x.","journal-title":"Kidney Int"},{"issue":"26","key":"385_CR9","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"GM Chertow","year":"2012","unstructured":"Chertow GM, Block GA, Correa-Rotter R, Dr\u00fceke TB, Floege J, EVOLVE Trial Investigators, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482\u201394. https:\/\/doi.org\/10.1056\/NEJMoa1205624.","journal-title":"N Engl J Med"},{"issue":"9","key":"385_CR10","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2215\/CJN.13081211","volume":"7","author":"M Fukagawa","year":"2012","unstructured":"Fukagawa M, Fukuma S, Onishi Y, Yamaguchi T, Hasegawa T, Akizawa T, et al. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. Clin J Am Soc Nephrol. 2012;7(9):1473\u201380. https:\/\/doi.org\/10.2215\/CJN.13081211.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"385_CR11","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2215\/CJN.07050714","volume":"10","author":"JB Wetmore","year":"2015","unstructured":"Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, et al. Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015;10(6):1031\u201340. https:\/\/doi.org\/10.2215\/CJN.07050714.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"385_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1744-9987.2008.00631.x","volume":"12","author":"H Komaba","year":"2008","unstructured":"Komaba H, Fukagawa M, KRN1493 Study Group. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study. Ther Apher Dial. 2008;12(1):44\u20139. https:\/\/doi.org\/10.1111\/j.1744-9987.2008.00631.x.","journal-title":"Ther Apher Dial"},{"issue":"4","key":"385_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transpl. 2011;26(4):1327\u201339. https:\/\/doi.org\/10.1093\/ndt\/gfq725.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"385_CR14","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2215\/CJN.01040308","volume":"3","author":"S Fishbane","year":"2008","unstructured":"Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol. 2008;3(6):1718\u201325. https:\/\/doi.org\/10.2215\/CJN.01040308.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"385_CR15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","volume":"94","author":"M Fukagawa","year":"2018","unstructured":"Fukagawa M, Shimazaki R, Akizawa T, Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018;94(4):818\u201325. https:\/\/doi.org\/10.1016\/j.kint.2018.05.013.","journal-title":"Kidney Int"},{"issue":"15","key":"385_CR16","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516\u201325. https:\/\/doi.org\/10.1056\/NEJMoa031633.","journal-title":"N Engl J Med"},{"issue":"1","key":"385_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfm534","volume":"23","author":"M Fukagawa","year":"2008","unstructured":"Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transpl. 2008;23(1):328\u201335. https:\/\/doi.org\/10.1093\/ndt\/gfm534.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"385_CR18","doi-asserted-by":"publisher","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","volume":"10","author":"SC Palmer","year":"2013","unstructured":"Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PloS Med. 2013;10(4):e1001436. https:\/\/doi.org\/10.1371\/journal.pmed.1001436.","journal-title":"PloS Med"},{"key":"385_CR19","doi-asserted-by":"publisher","unstructured":"Y. Gincherman, K. Moloney, C. McKee, Coyne DW. Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients. Hemodial Int. 2010; 14(1); 68\u201372. https:\/\/doi.org\/10.1111\/j.1542-4758.2009.00397.x","DOI":"10.1111\/j.1542-4758.2009.00397.x"},{"issue":"5","key":"385_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","volume":"48","author":"D Padhi","year":"2009","unstructured":"Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303\u201311. https:\/\/doi.org\/10.2165\/00003088-200948050-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"385_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/sdi.12734","volume":"31","author":"KE Eidman","year":"2018","unstructured":"Eidman KE, Wetmore JB. Treatment of secondary hyperparathyroidism: how do cinacalcet and etelcalcetide differ? Semin Dial. 2018;31(5):440\u20134. https:\/\/doi.org\/10.1111\/sdi.12734.","journal-title":"Semin Dial"},{"issue":"3","key":"385_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/1744-9987.13434","volume":"24","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M. Evocalcet: a new oral calcimimetic for dialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2019;24(3):248\u201357. https:\/\/doi.org\/10.1111\/1744-9987.13434.","journal-title":"Ther Apher Dial"},{"issue":"1","key":"385_CR23","doi-asserted-by":"publisher","first-page":"F395","DOI":"10.1152\/ajprenal.00100.2006","volume":"292","author":"H Segawa","year":"2007","unstructured":"Segawa H, Yamanaka S, Onitsuka A, Tomoe Y, Kuwahata M, Ito M, et al. Parathyroid hormone-dependent endocytosis of renal type Iic Na-Pi cotransporter. Am J Physiol Renal Physiol. 2007;292(1):F395-403. https:\/\/doi.org\/10.1152\/ajprenal.00100.2006.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"385_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317(2):156\u201364. https:\/\/doi.org\/10.1001\/jama.2016.19468.","journal-title":"JAMA"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-022-00385-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-022-00385-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-022-00385-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T06:23:07Z","timestamp":1654323787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-022-00385-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1007\/s40268-022-00385-4","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"assertion":[{"value":"7 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declartions"}},{"value":"SKK sponsored this study.\u00a0SKK paid the Open Access fee for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Fumihiko Koiwa and Masafumi Fukagawa received honoraria from SKK for consulting and lectures. Daisuke Honda is an employee of SKK. Tadao Akizawa received consulting fees from SKK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted at SOUSEIKAI Sumida Hospital, Tokyo, Japan. All the study protocols and informed consent documents were reviewed and approved by the Japanese Pharmaceuticals and Medical Devices Agency and the investigation review board of the Hakata Clinic. This study was conducted in compliance with the Helsinki Declaration and comparable ethical standards, Good Clinical Practice guidelines, and other regulatory requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The dataset from this study is not available in any open data repository.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All participants provided written informed consent before participating in the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Fumihiko Koiwa, Rie Yazawa, and Tadao Akizawa substantially contributed to the study design and the acquisition and interpretation of the data. Masafumi Fukagawa and Daisuke Honda substantially contributed to the analysis and interpretation of data. All authors critically revised the report, commented on drafts of the manuscript, and approved the final report.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}